Morgan Stanley: Sino Biopharmaceutical's (01177) Acquisition of LaNova Medicine Reasonably Priced; HK$4.9 Target Maintained

Stock News
07-16

Morgan Stanley affirms Sino Biopharmaceutical Limited's (01177.HK) acquisition of the remaining 95.09% stake in LaNova Medicine for US$501 million as reasonably priced. This follows Sino Biopharm's earlier investment of RMB142 million for a 4.91% ownership. The transaction valuation reflects LaNova's promising late-stage pipelines and two completed out-licensing agreements. This strategic move grants Sino Biopharm access to multiple technological platforms, significantly strengthening its oncology portfolio. Morgan Stanley reiterates its "Overweight" rating with a HK$4.9 target price, anticipating enhanced tumor pipeline development through this acquisition.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10